This study investigates the effects of zigakibart in adults diagnosed with IgA nephropathy. IgA nephropathy is a rare kidney disease where an antibody called immunoglobulin A builds up in the kidneys, causing inflammation and damage to the organ’s filtering units. The purpose of the study is to determine if treatment with zigakibart can change the course of this disease. The medication will be administered via subcutaneous injection, which is a shot given into the fatty tissue just under the skin.

During the study, participants will receive the medication over a period of up to two years. Researchers will monitor how the treatment affects various markers of kidney health. This includes looking at kidney tissue through a biopsy, which is a procedure to remove a small piece of the organ for examination, to check for changes in inflammation and the severity of the disease. Additionally, blood and urine tests will be used to track kidney function, such as the estimated glomerular filtration rate, which is a measure of how well the kidneys filter waste from the blood, and the amount of protein present in the urine.

Other aspects of the study involve monitoring how the medication affects the body’s immune system, including the response to vaccines and the levels of different immunoglobulins, which are proteins that help the immune system fight infections. The concentration of the drug in the blood and the presence of any antibodies created by the body against the medication will also be tracked. This allows for a comprehensive look at how zigakibart influences both the disease process and the body’s overall response to the treatment.